SANUWAVE Health Inc

In a Stage 4 decline, both medium- and long-term biases remain bearish. Despite an extreme oversold bounce, price is still below the downward-sloping 9/21 EMAs without any clear rejection at resistance levels. With no definitive short-side trigger, execution should be deferred, awaiting a pullback into the EMA zone for a structurally sound short entry.

• ↑Q1 2026 revenue rose to $9.6 M (+3% YoY), the highest Q1 in company history.
• ↑Management forecasts Q2 sales of $11.1–11.6 M, implying 10–15% YoY growth.
• ↓Q1 operating loss of $1.1 M contrasts with prior $0.6 M profit.